TrialJournal of neurology2020

Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.

Ralf Gold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.